Novartis: U.S. Court of Appeals, Federal Circuit (CAFC), upholds Gilenya(r), (fingolimod), dosage regimen patent

January 4, 2022 ---¡sel, January 4, 2022נToday, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its..